About Translational Drug Development (TD2)
Translational Drug Development (TD2) is a world-class drug development organization specializing in getting the newest and best oncology treatments to cancer patients as quickly as possible.
To focus cutting-edge science into translational solutions. Driven by science and motivated by patients, TD2 strives to make a significant impact on cancer.+
World class preclinical, regulatory and clinical science aligned with unique patient identification and recruitment solutions and the ability to execute with urgency.+
“Development of new medicines requires both the best possible preclinical and clinical science. It also demands working with a great sense of urgency. The TD2 team provides innovative solutions that give new medicines the best chance to work for patients with cancer. With expert capabilities that support early discovery, pharmacokinetics, regulatory affairs and clinical development through Phase II, TD2 represents a comprehensive solution for oncology-focused companies.”
Daniel D. Von Hoff, MD, FACP, Chief Development Officer - TD2
“TD2 has a rich scientific heritage and has successfully identified, translated and applied -omics driven outcomes to speed the development of new oncology medicines, and to identify those cancer patients most likely to have clinical benefit from these new drugs.”
Jeffrey Trent, PhD, FACMG, President and Research Director - Translational Genomics Research Institute (TGen)
Leading patient engagement and mobile care management solution and precision oncology CRO partner to revolutionize patient engagement in clinical trials Scottsdale, AZ and Seattle, WA – April 20, 2015 — TD2, the precision oncology CRO, and Navigating Cancer, the...
Collaboration to provide expanded use of Paradigm Cancer Diagnostic (PCDx™) service by oncologists across large oncology network SCOTTSDALE, AZ and ANN ARBOR, MI Monday, April 20, 2015 -- Paradigm and Translational Drug Development (TD2) today announced a partnership under...
Responsibility for Pancreatic Cancer Research Team Moves to Seattle Non-Profit Institution Seattle, WA. September 8, 2014 Seattle’s own Cancer Research And Biostatics (CRAB), and Translational Drug Development (TD2) in Scottsdale, would like to jointly announce CRAB’s assumption of responsibility for ...
Please submit your e-mail to subscribe to TD2 news